Tempus AI (NASDAQ:TEM) Cut to Market Perform at William Blair

William Blair cut shares of Tempus AI (NASDAQ:TEM) from an outperform rating to a market perform rating in a research note released on Wednesday morning, Marketbeat Ratings reports.

A number of other brokerages also recently weighed in on TEM. Loop Capital cut their price objective on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday, January 14th. TD Cowen reissued a “buy” rating and issued a $74.00 price objective (up from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Guggenheim started coverage on Tempus AI in a research note on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective on the stock. Bank of America raised their price objective on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday, December 13th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $56.00 price objective on shares of Tempus AI in a research note on Tuesday, January 14th. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $58.55.

Tempus AI Price Performance

TEM opened at $89.44 on Wednesday. Tempus AI has a fifty-two week low of $22.89 and a fifty-two week high of $91.45. The business has a 50-day moving average of $46.60 and a 200-day moving average of $50.29. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Insider Activity at Tempus AI

In other Tempus AI news, major shareholder Bradley A. Keywell sold 265,000 shares of Tempus AI stock in a transaction on Friday, January 17th. The stock was sold at an average price of $35.10, for a total value of $9,301,500.00. Following the completion of the transaction, the insider now owns 15,218,365 shares in the company, valued at approximately $534,164,611.50. The trade was a 1.71 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Andrew Polovin sold 51,504 shares of Tempus AI stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $42.39, for a total value of $2,183,254.56. Following the completion of the transaction, the executive vice president now owns 246,085 shares of the company’s stock, valued at approximately $10,431,543.15. The trade was a 17.31 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 2,401,779 shares of company stock valued at $115,707,361 in the last 90 days.

Institutional Investors Weigh In On Tempus AI

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Wells Fargo & Company MN raised its position in shares of Tempus AI by 13.2% during the fourth quarter. Wells Fargo & Company MN now owns 2,384 shares of the company’s stock worth $80,000 after acquiring an additional 278 shares during the last quarter. First Horizon Advisors Inc. bought a new stake in shares of Tempus AI during the third quarter worth $30,000. Geode Capital Management LLC raised its position in shares of Tempus AI by 0.4% during the third quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock worth $7,537,000 after acquiring an additional 539 shares during the last quarter. Operose Advisors LLC acquired a new stake in shares of Tempus AI during the fourth quarter worth $25,000. Finally, Prestige Wealth Management Group LLC grew its stake in shares of Tempus AI by 910.4% during the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock worth $36,000 after purchasing an additional 965 shares during the period. Institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.